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Introduction. Osteoarthritis (OA) is a degenerative joint disease characterized by articular cartilage degradation, subchondral
damage, and bone remodelling, affecting most commonly weight-bearing joints, such as the knee and hip. The loss of cartilage
leads to joint space narrowing, pain, and loss of function which could ultimately require total joint replacement.TheWnt/𝛽 catenin
pathway is involved in the pathophysiology of OA and has been proposed as a therapeutic target. Endogenous and pharmacological
inhibitors of this pathway were recently investigatedwithin innovative therapies including the use of platelet-rich plasma (PRP) and
mesenchymal stem cells (MSCs).Methods. A reviewof the literaturewas performed on the PubMed database based on the following
inclusion criteria: article written in English language in the last 20 years and dealing with (1) the role of Wnt-𝛽 catenin pathway
in the pathogenesis of osteoarthritis and (2) pharmacologic or biologic strategies modulating the Wnt-𝛽 catenin pathway in the
OA setting. Results. Evidences support that Wnt signalling pathway is likely linked to OA progression and severity. Its inhibition
through natural antagonists and new synthetic or biological drugs shares the potential to improve the clinical condition of the
patients by affecting the pathological activity of Wnt/𝛽-catenin signalling. Conclusions. While further research is needed to better
understand themechanisms regulating themolecular interaction betweenOA regenerative therapies andWnt, it seems that biologic
therapies for OA exert modulation on Wnt/𝛽 catenin pathway that might be relevant in achieving the beneficial clinical effect of
those therapeutic strategies.
1. Introduction
Osteoarthritis (OA) is a degenerative joint disease char-
acterized by articular cartilage degradation, subchondral
damage, and bone remodelling, affecting most commonly
weight-bearing joints such as the knee and hip. Many treat-
ment options are currently available for OA, ranging from
conservative to surgical measures and regenerative medicine
approaches. Despite wide research efforts on OA, there is
a huge unmet need in effective therapies that ultimately
change the natural history of the disease. Recently intro-
duced autologous treatments, such as platelet-rich plasma
(PRP) and mesenchymal stem cells (MSC), have been largely
investigated in orthopaedic surgery and proposed as OA
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treatments. The rationale for the use of these biologic prod-
ucts is based on their capability of modulating the joint
environment by releasing a series of growth factors and
immune-modulatory molecules that could play a beneficial
role in reducing the local inflammation and promoting
cartilage and synovium anabolism [1]. From a pathogenetic
standpoint, cartilage homeostasis and bone remodelling are
regulated by a complex network of metabolic pathways and,
among these, the Wnt/𝛽-catenin pathway is activated in OA
and is emerging as a regulator of tissue repair and fibrosis [2].
It has been hypothesized that PRPmay protect chondrocytes
activated by IL-1𝛽 via inhibitingWnt/𝛽-catenin signalling [3].
The aim of the present review is to shed light on the current
concepts concerning the role of the Wnt/𝛽-catenin pathway
in the pathogenesis of OA, and understanding the potential
therapeutic implications in the field of regenerative medicine.
2. Methods
A review of the literature was performed on the PubMed
database by two independent authors (CE and VND). The
research string used was the following:
“((Wnt OR catenin) OR (IL 1 AND Wnt) OR (dkk1 and
Wnt)) AND (osteoarthritis treatment OR PRP OR platelet
rich plasma OR (MSC AND osteoarthritis))”
The inclusion criteria were in vitro articles written in
English language, published in the last 20 years, and dealing
with (1) the role of the Wnt-𝛽 catenin pathway in the patho-
genesis of osteoarthritis and (2) pharmacologic or biologic
strategies modulating the Wnt-𝛽 catenin pathway in the OA
setting.
A total of 168 articles were retrieved: first, the articles
were screened by title and abstract and then the full texts
of the selected articles were analyzed. Reference lists from
the selected papers were also screened and, at the end of
the selection process, 14 papers in total were included in
the present review. Relevant data were then extracted and
collected in a unique database with the consensus of the two
aforementioned authors.
3. Results
Of the 14 articles included in this review [3–16] (Tables 1, 2,
and 3), ten focused on the molecular mechanism in which
OA, Wnt, and endogenous inhibitors are associated [5–14],
two on PRP and its potential to modulate the Wnt pathway,
and two on new potential pharmacological inhibitors [4, 16].
Most of the studies reported how the Wnt inhibition can be
a potential new target for OA treatment and explored how
this can improve the clinical outcome of patients. Early inves-
tigations of the Wnt/𝛽-catenin pathway modulation with
biologicals and regenerative therapies demonstrate promise.
However, in the absence of any long-term clinical data in
a substantial number of clinical subjects, further study is
required to elucidate proof of concept, safety, and efficacy.
What emerged from the present review of the literature is
an increasing interest in therapeutic approaches to influence
this signalling way, especially with PRP, but also with other
biologics, and new experimental inhibitors.
3.1. Wnt Canonical and Noncanonical Signalling Pathways:
A Comprehensive Synthesis. The Wnt family of proteins
includes morphogens associated with embryonic formation,
tissue repair, fibrosis, and homeostasis of the bone and joint
tissues, among others [4, 17].
Wnt regulates multiple signalling cascades, including
one 𝛽-catenin–dependent (canonical) and two 𝛽-catenin–
independent pathways [18].TheWnt/𝛽-catenin canonical sig-
nalling pathway is initiated by the binding of theWnt proteins
to their 7-pass transmembrane Frizzled (Fz) receptors and
results in the activation of the central player of the pathway,
downstream 𝛽-catenin. To activate the canonical signalling
pathway, Wnt ligands must bind to both Fz receptors and the
coreceptor low-density lipoprotein receptor-related protein
(LRP) 5/6. This binding further enables the release of 𝛽-
catenin from its intracellular binding complex [composed
of glycogen synthase kinase-3𝛽 (GSK3𝛽), caseine kinase 1-
𝛼 (CK1𝛼), adenomatous polyposis coli (APC), and Axin2],
which in the Wnt-off state phosphorylates and ubiquitinates
𝛽-catenin, leading to its degradation in proteasomes [19, 20].
Alternatively, in the Wnt-on state, or when a Wnt ligand is
available, Fz receptors and LRP 5/6 are activated upon ligand
binding. The receptor occupancy leads to the phosphoryla-
tion of LRP 5/6 by Gsk3𝛽 and Ck1𝛼 in its cytoplasmic region,
followed by the recruitment of the dishevelled (DVL)1–3
andaxin [20], which inhibits the destruction of the complex
and the stabilization of 𝛽-catenin in the cytoplasm. The acti-
vated 𝛽-catenin translocates into the nucleus where it binds
the transcription factors of T cell factor (TCF)/lymphoid
enhancer factor (LEF) transcription factors, converting them
from repressors to activators causing the transcription of
targeted genes [21, 22]. The two noncanonical pathways
include a Ca2+ dependent (transmitted via calmodulin kinase
II and protein kinase C) and a planar cell polarity pathway
(transmitted via small GTPases) and both contribute to the
regulation of cytoskeletal organisation, cell differentiation,
and communication [22–24]. Members of the Wnt ligand
family, currently including 19 members, activate either the
canonical or the noncanonical pathway, according to the
receptor they bind to as mentioned above [25]. Ultimately,
both 𝛽-catenin dependent and independent cascades are
demonstrated in the joint where the noncanonical pathways
appear to counterregulate the canonical Wnt pathway [26].
The Wnt signalling pathways also undergo strict regula-
tion by different inhibitors, including the family of secreted
frizzled related proteins (SFRP) 1-4 and Wnt inhibitor factor
(WIF) which act as a soluble scavenger of Wnt ligands
[27]; other molecules, such as members of Dickkopf (DKK)
family and sclerostin, bind to LRP 5/6 and interfere with the
Wnt downstream activation cascade disabling their ability to
interact with Wnt-Fz [17, 28], among other inhibitors [28].
The dysregulation of the Wnt canonical pathway is
believed to be central to the pathogenesis of cancer,
chronic inflammation, and degenerative diseases, and natural
inhibitors are thus under investigation for therapeutic pur-
pose. The mechanisms by which the Wnt pathway is influ-
enced by inflammation remain unclear, but its involvement
is well established in new bone formation through osteoblast
differentiation and function, in the role of TNF𝛼 as a major
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Table 1: In vitro animal studies included.
Reference Author Subjects Pathway involved Results
[3] J. Wu et al.(2018)
New Zealand white rabbit
chondrocytes
PRP andWnt/
𝛽-catenin
A lower expression level of
WNT1 and 𝛽-catenin than
in another group treated
with IL-1𝛽 was observed
[4] C.Lietman etal. (2018)
OA-induced murine model
synovial fibroblasts and
chondrocytes
XAV-939
After it was injected inside
the joint, a reduction of the
cartilage degradation and
synovial inflammation was
observed
[6] L. Lodewyckxet al. (2012)
Cell culture (ATDC5) and
mouse ribcage and tibial
plateau chondrocytes from
Frzb−/− and wild type mices
Wnt/𝛽-catenin
Overexpression of FRZB
coupled with an
up-regulation of aggrecan
and Col2a1 and
down-regulation of Col3a1
and Col5a1. FRZB is in strict
relationship to Wnt pathway
[7] T. Yuasa et al.(2008)
New Zealand rabbit
articular chondrocytes and
guinea pig knee
chondrocytes
Wnt/𝛽-catenin
Wnt/beta-catenin
signalling is a powerful
stimulator of chondrocyte
matrix catabolic action and
may be part of mechanisms
leading to excessive
remodelling and
degradation of cartilage
matrix in age-associated
joint pathologies
[8] M. Zhu et al.(2009)
Adult Col2a1-CreERT2
transgenic mice
chondrocytes
𝛽-catenin
Activation of beta-catenin
signalling in articular
chondrocytes in adult mice
leads to the premature
chondrocyte differentiation
and the development of an
OA-like phenotype.
[10] Y. Tamamuraet al. (2005)
transgenic mice expressing
a fusion mutant protein of
𝛽-catenin and LEF
(CA-LEF) in nascent
chondrocytes
𝛿-𝛽-Catenin
Increase of proteins
involved in cartilage matrix
degradation (MMP-13,
ADAMTS-4, ADAMTS-5
and RUNX-2)
[11] Shi et al.(2016)
Sprague-Dawley rats
(n=24) articular
chondrocytes
WNT5A
SilencingWNT5AmRNA
prevented degradation of
COL2
[15] Wang D. et al(2018)
100 BALB/c transgenic
mice osteoclasts PRP/RANKL/Wnt
The study indicated that
PRP inhibits osteoclast
differentiation through
activation of the Wnt
pathway and inhibiting
RANKL
driver of bone destruction in arthritis, and upregulating the
Wnt antagonist Dkk-1 and inhibiting new bone formation. In
particular, a prolonged mechanical stress can induce TNF-𝛼
but also IL-1 expression in chondrocytes [29], thus suggesting
a possible role for both cytokines in OA.
3.2. Role of the Wnt Pathway in OA Development. The
pathological processes involved in OA have been widely
investigated during the last decades and can be summa-
rized in articular cartilage degradation, subchondral bone
remodeling, and synovitis regulated by a complex network
of differentmolecular pathways, including theWnt/𝛽-catenin
signaling network in the homeostasis of bone and cartilage
[30–32]. WNTs, a large family of 19 secreted glycoproteins,
bind their frizzled (FZD) receptors preventing 𝛽-catenin to
be phosphorylated and disposed, leading to its accumulation
and subsequent migration to the nucleus, where it activates
the transcription of different target genes [33].
In OA, this pathway is enhanced in both human and ani-
mal models [6–9, 34]. There is an increase in the expression
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Table 2: In vitro human studies included.
Reference Author Subjects Pathwayinvolved Results
[5] J. Wu et al.(2017)
Human chondrocytes from
OA (n=57) and healthy
subjects (n=6) knees
SOST/Wnt SOST may not have beneficial effects onchondrocytes affected by OA
[9] F. Dell’Accioet al. (2008)
human articular
chondrocytes (explants 24
hours after mechanical
injury) from 8 patients
Wnt family
A systematic analysis of the Wnt
signalling pathway revealed up-regulation
of Wnt-16, down-regulation of FRZB,
up-regulation of Wnt target genes, and
nuclear localization of beta-catenin in
injured cartilage
[13] S.-G. Gao etal. (2016)
40 patients with various
stages of primary OA
cartilage and subchondral
bone from tibial plateau
WIF-1
Patients with disease had significantly
decreasedWIF-1 levels. Thus,WIF-1
levels were negatively correlated with the
severity of the disease
Table 3: In vitro both human and animal studies included.
Reference Author Subjects Pathwayinvolved Results
[12] L. Chen et al. (2016)
C57BL/6 transgenic mice
and OA human (n=10)
articular chondrocytes
EZH2
EZH2 level was found significantly
increased. Pharmacological inhibition of
EZH2 silenced 𝛽-catenin signalling
pathway and delayed OA progression in
mice
[14] H. Oh et al. (2012) Human and mouse OAmodel chondrocytes DKK-1/Wnt
Overexpressing Dkk-1 by intra-articular
injection significantly reduced
progression of OA in mice induced with
DMM thanks to the inhibition of
Wnt-mediated expression of catabolic
factors
[16] Deshmukh V. et al. (2018)
Cell culture of
bone-marrow-derived
human mesenchymal stem
cells (hMSCs) and in vivo
studies in a rodent acute
cruciate ligament tear and
partial medial
meniscectomy (ACLT +
pMMx) OA model
SM04690
SM04690 induced hMSC differentiation
into mature, functional chondrocytes and
decreased cartilage catabolic marker
levels compared to vehicle. A single
SM04690 intra-articular (IA) injection
was effective in a rodent OA model
levels of different proteins involved in OA and facilitating
cartilage matrix degradation, including MMP-13, ADAMTS-
4, ADAMTS-5, and RUNX-2C [10]. One of the initial steps
of OA physiopathology is the destruction of collagen type II
(COL2) and this phenomenon is activated by the upregula-
tion of WNT5A in rat model of OA-chondrocytes. Silencing
WNT5A mRNA through delivering small interfering RNA
by a lentiviral vector prevented degradation of COL2 [11].
The WNT/𝛽-catenin pathway can also be activated by the
induction of the histone methyltransferase enhancer of zeste
homologue 2 (EZH2) [12]. EZH2 level was found significantly
increased in chondrocytes of OA patients compared to
healthy humans, along with high-level expression of MMP-
13, ADAMTS-5, and COLX. Pharmacological inhibition of
EZH2 silenced 𝛽-catenin signaling pathway and delayed OA
progression in mice. Evidence from in vivo and in vitro
studies indicates that synoviocytes, chondrocytes, and cells
from other joint tissues produce cytokines in response to
mechanical or oxidative stress or degradation products [35].
The in vitro mechanical loading data support the hypothesis
that static compression stimulates the depletion of proteo-
glycans and damage to the collagen network and decreases
the synthesis of cartilage matrix proteins, through the action
of reactive oxygen species (ROS) and TNF-𝛼 [36], whereas
dynamic cyclic compression increases matrix synthetic activ-
ity inhibiting IL-1-induced cartilage matrix degradation [37].
IL-1𝛽 is a key proinflammatory cytokine that drives OA
progression by inducing the expression of cartilage degrading
enzymes, such as matrix metalloproteinases (MMPs) [38]
and nitric oxide (NO) expression involved in joint damage.
NO is highly expressed by OA chondrocytes and cartilage
and inhibits both the synthesis of proteoglycan and colla-
gen, activates MMPs, mediates chondrocyte apoptosis, and
promotes inflammatory responses, ultimately resulting in a
BioMed Research International 5
major catabolic effect. A recent study on human chondrocytes
reported that IL-1𝛽 decreases the expression of DKK1 and
FRZB through the upregulation of nitric oxide synthase, and
the activation of Wnt target gene transcription [39].
3.3. Genetic Variability of the Wnt Pathway. The key role of
Wnt in joint homeostasis, OA development, and treatment
is demonstrated by several studies, which provide evidence
of the association between single nucleotide polymorphisms
(SNPs) in different genes encoding for proteins of the
pathway associated to disease. Variants of the gene of WNT
inhibitor sFRP-3/FRZBwere associated with OA, reducing its
capacity to antagonizing 𝛽-catenin [40]. A SNP in the frizzled
coreceptor LRP5 prevents the Wnt signaling antagonists
SOST and Dkk-1 from binding, inducing spinal OA [41].
More recently, a SNP in WNT1 inducible signaling pathway
protein 1 (WISP1), a Wnt-induced protein, has been related
to spineOA [42]. Another important consideration about the
Wnt/𝛽-catenin pathway comes from a genome-wide analysis
of gene expression in knee cartilage affected by OA [43]. Net-
work analysis of RNA-sequencing identified the presence of
two different major pathogenetic pathways: one with higher
expression of chondrogenic genes and altered expression of
chemokine signaling, inflammasome, and innate immune
response and the other with a more osteogenic phenotype
and altered WNT signaling and mechanoreceptors. This
observation may well represent a new starting point for the
stratification of patients with OA, based on the phenotype of
the disease: i.e., inflammatory and load-related, thus allowing
more specific and individualized targeted treatments.
3.4. Endogenous Inhibitors of Wnt. The Wnt pathway is
controlled by endogenous antagonists and the expression
levels of someof these inhibitorsmay decrease in parallel with
OAprogression, thus supporting a link betweenWnt pathway
and OA pathogenesis.
3.4.1. Sclerostin. Bone tissue cells are actively involved in the
development of OA by synthesizing molecules that regulate
the joint homeostasis. In particular, osteocytes produce scle-
rostin, an endogenous Wnt/𝛽-catenin inhibitor that plays an
important role in maintaining cartilage integrity, as demon-
strated in a study on a murine model of OA [5]. Healthy and
OA chondrocytes were incubated with 250 ng/ml sclerostin
for 48h and as a result decreased mRNA expression levels of
𝛽-catenin have been obtained in both groups. Treatment with
sclerostin also inhibited the expression levels of downstream
catabolic effector genes RUNX-2, MMP-13, ADAMTS-4,
and ADAMTS-5 in healthy chondrocytes. Anabolic factor
COL2A1 expression increased with sclerostin challenge and
these effects have not been observed in OA chondrocytes
compared with the control group, indicating that sclerostin
may not have beneficial effects on OA chondrocytes. Chon-
drocytes were also incubated with 10 ng/l IL-1𝛼 for 48h,
resulting in increased mRNA expression levels of 𝛽-catenin.
Therefore IL-1𝛼 may control cartilage degradation via over-
activation of the WNT/𝛽-catenin pathway.
The protective role of sclerostin through the inhibi-
tion of Wnt was also suggested in another study [44].
Sclerostin-knockout mice with DMM had a high OA score,
increased expression of aggrecanases and type X collagen,
and cartilage damage with inhibition of bothWNT canonical
and noncanonical pathways.
3.4.2. Wnt-Inhibitor Factor-1. The WNT-inhibitory factor 1
(WIF-1) is a potent extracellular WNT antagonist whose
role has been investigated in many trials. Looking at its
implications in articular degenerative pathology, it was found
that patients with OA had significantly decreased WIF-1
levels compared to control, and WIF-1 levels also negatively
correlatedwith the severity of the disease, as described byGao
et al. who analyzed specimens obtained from40 patients with
various stages of knee OA [13].
3.4.3. Dickkopf. Dkk-1 is also a Wnt antagonist and is acti-
vated in osteocytes of the subchondral bone as well as in
osteophytes and synovium after 4-6 weeks, as shown in a
group of Topgal mice (transgenic mice that express Beta-
galactosidase in the presence of the lymphoid enhancer bind-
ing factor 1/transcription factor 3 (LEF/TCF) and activated
Beta-catenin) with OA induced by meniscectomy. The Dkk-
1 expression is also elevated in chondrocytes of control mice
but decreased greatly in knees of mice that underwent menis-
cectomy, starting from week 4 [45]. In a 2012 study, Dkk-
1 overexpression by intra-articular injection significantly
reduced progression of OA in mice induced with surgical
destabilization of the medial meniscus. This was linked
to Dkk-1 capacity to inhibit Wnt-mediated expression of
catabolic factors, such as MMP-13, showing how Dkk-1 may
exert a protective role in OA [14]. But data are conflicting.
In 2010 Weng et al. demonstrated that elevated Dkk-1 levels
were associated with a high Mankin score and high serum
levels of cartilage degradation markers in murine models.
Dkk-1 knockdown increased 𝛽-catenin but attenuated the
expression of inflammatory factors (TLR-4, TLR-9, IL-1𝛽, and
TNF-𝛼), the apoptosis regulator Bax, MMP-3, and RANK-
L and these data suggest that Dkk-1 knockout produced
less cartilage destruction and less subchondral damage in
OA knee [46]. Dickkopf-3 (Dkk-3) is also a member of the
Dkk family of WNT antagonists and elevated concentrations
inhibited the loss of proteoglycan and collagen from cartilage
in amodel of OA obtained with IL-1𝛽 and oncostatin-M [47].
3.4.4. Pharmacological Inhibitors of Wnt. Recently, new
potential drugs which selectively inhibit the Wnt pathway
have been investigated and in a phase 1 study, the inhibition
of Wnt/𝛽-catenin pathway in mice led to a less severe OA.
The small-molecule “XAV-939”, a tankyrase inhibitor that
promotes the phosphorylation of 𝛽-catenin leading to its
destruction, was intra-articularly injected in a murine model
of traumatic OA, obtained by a surgical destabilization of the
medial meniscus and a reduced cartilage degradation and
synovial inflammation was observed. XAV-939, along with
the small-molecule inhibitor C113, was also tested in vitro
on human synovial fibroblasts and OA-derived chondrocytes
and led to an attenuated proliferation and type I colla-
gen synthesis in synovial fibroblasts while in chondrocytes,
although there was no affection in proliferation. In further
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detail, the Wnt inhibition led to an increased transcription
of COL2A1 and PRG4, two genes which are downregulated
in the cartilage affected by OA [4]. Another preclinical study
evaluated the effectiveness of SM04690, a small-molecule
Wnt pathway inhibitor, both in cultured human mesenchy-
mal stem cells (hMSC) and in rodent OA model. The new
potential drug induced hMSC differentiation into mature,
functional chondrocytes and decreased cartilage catabolic
marker levels compared to vehicle. A single SM04690 intra-
articular (IA) injection was effective in a rodent OA model,
with increased cartilage thickness, evidence for cartilage
regeneration, and protection from cartilage catabolism [16].
3.4.5. Biological Therapies and Wnt. PRP is an autologous
blood derivate widely used for treating several muscu-
loskeletal diseases and, despite limited evidence, its use has
demonstrated promising results also in OA. The effects on
OA progression and clinical outcome can be related to the
growth factors contained in it. The effects of PRP on the
WNT/𝛽-catenin pathway were studied in New Zealand white
rabbit chondrocytes. These chondrocytes were cultured, and
a group was treated with PRP, whereas another group was
treated by IL-1b: concentrations of cartilage degradation
proteins CTX-II and COMP were lower in PRP group and
less ultrastructural abnormalities and enhanced chondrocyte
proliferation were also observed by electron microscopy [3].
Wang et al. reported that PRP inhibits bone degradation
via downregulation of osteoclast-associated genes induced
by RANKL. A gene expression profile chip analysis revealed
the overexpression of WNT/𝛽-catenin pathway genes and an
important downregulation of Dkk1, which was demonstrated
to enhance osteoclast genesis [48], thus proving conflicting
data [15]. Similar to PRP, intra-articular MSC, both derived
from the adipose tissue and bone marrow, have been used
for the treatment of OA.The therapeutic mechanism involves
Wnt pathway and MMP-13, TNF-𝛼, and IL-1𝛽 expression
[49], even though until now there is a lack of clinical
efficacy evidence. As shown by Cassano et al, the growth
factors concentrations of whole blood, PRP, and bonemarrow
concentrate differ significantly [50], and the higher presence
of factor such as IL 1𝛽 capable of influencing Wnt pathway
can potentially change the clinical outcome of OA patients
and should be investigated. We strongly encourage further
clinical studies associated with a quantitative analysis of the
different autologous therapies used in relationship with the
WNT/𝛽-catenin pathway.
4. Discussion
In recent years, there has been a growing interest in trying
to identify molecular patterns to target as a therapeutic
strategy for OA, which represents the most common diseases
of musculoskeletal system, involving millions of patients
worldwide [51]. In line with the progress made in other
fields of medicine, identifying novel pathways has led to the
understanding that OA treatment should be multimodal in
order to maximize the clinical outcome.
In the present review, we described one of the molecular
pathways that has recently come into light for its role in
OA development: the Wnt pathway. Wnt family of proteins
plays a central role in several signalling cascades that are
ultimately involved in increasing the inflammation in the
articular environment and stimulating the release of catabolic
molecules such as metalloproteinases, which are responsi-
ble for cartilage degradation, thus feeding a vicious circle
between inflammation and progressive degeneration, which
involves all the articular tissues [5, 6, 30, 47]. Interesting
in vitro findings have shown that the Wnt pathway is
significantly involved in type II collagen degradation and
chondrocyte apoptosis, thus justifying the interest in deep-
ening our knowledge of this family of proteins [33–35]. The
involvement of Wnt pathway in the pathogenesis of OA has
been investigated and described in many animal models, as
shown by the present review: it may be argued that species-
specific patterns exist that could limit the generalization
of results and their application in the human setting but,
despite this limitation, the search for strategies to modulate
this pathway seems justified and the principal aim is to
develop new pharmacological strategies that could stop OA
progression at a molecular level. The most common conser-
vative management of OA is by intra-articular injection: in
recent times, traditional products such as corticosteroids and
hyaluronic acid have been flanked by novel therapies based
on immunomodulatory molecules and also on “autologous”
derivatives such as PRP and MSCs that have the potential
advantage of minimizing side effects due to their autologous
nature [52]. Although limited evidence suggests that these
biologic products could exert a modulation on the Wnt path-
way [3, 45, 46, 53], further studies are needed to understand
whichmechanisms are involved inWnt-pathway modulation
and how to take full advantage of PRP andMSCs concentrate
in the control of OA progression. These powerful biologic
products can be regarded as a reservoir of many bioactive
molecules: understanding their role and the pathways they
can influence will open the possibility of manipulating these
products to obtain “autologous” drugs with specific biologic
actions within the joint.
There is also the opportunity for new synthetic “on-the-
shelf” drugs to be developed, to influence and modulate
these specific pathways. In the present review, we described
some endogenous inhibitors of Wnt-pathway that could be
exploited to this purpose in the near future.
Beyond the aspects related to OA therapy, the awareness
on the differentmolecular pathways involved inOAonset and
progression could stimulate further effort in the field of “early
diagnosis” and “stratification” of patients affected by OA. At
present, clinicians lack any reliable biomarker to identify OA
in its early stages and even the definition of OA is too generic,
since under this name we include very different pathological
entities, ranging from posttraumatic conditions to overload-
based OA (i.e., following meniscectomy) to inflammatory-
based disease [54]. Each of these entities has peculiar patho-
genetic features and, therefore, should be addressed differ-
ently. Therefore, the present review shows that molecular
targets are among the frontiers of future therapeutic strategies
in the treatment of OA: deeper insights into this field will
hopefully lead to developing products, as both “intelligent”
drugs and autologous derivatives, that could better modulate
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specific signalling pathways responsible for the progression
of OA. Beyond this, better knowledge of the many molecular
cascades involved in inflammatory OA will help in the future
basic researchers and clinicians to stratify patients according
to the molecular features of their OA, thus offering the
possibility of selecting a “personalized” therapeutic approach
to their disease [55].
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